Mercados españoles cerrados

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
73,25+0,24 (+0,33%)
Al cierre: 04:00PM EDT
73,39 +0,14 (+0,19%)
Después del cierre: 07:59PM EDT

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo18.000

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Daniel P. O'DayChairman & CEO7,27MN/A1964
Mr. Andrew D. DickinsonExecutive VP & CFO2,94MN/A1970
Ms. Deborah H. TelmanExecutive VP of Corporate Affairs, General Counsel & Corporate Secretary2,32MN/A1965
Ms. Johanna MercierChief Commercial Officer3,32MN/A1971
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer3,07MN/A1964
Ms. Sandra PattersonSenior VP, Corporate Controller & Principal Accounting OfficerN/AN/A1967
Ms. Jacquie Ross C.F.A.Vice President of Investor RelationsN/AN/AN/A
Ms. Jyoti K. MehraExecutive Vice President of Human ResourcesN/AN/A1976
Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & PortfolioN/AN/A1962
Dr. Rudolf ErtlSenior Vice President of Commercial Operations of Australia, Canada, EuropeN/AN/A1946
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gobierno corporativo

El ISS Governance QualityScore de Gilead Sciences, Inc., a día 1 de marzo de 2024, es 1. Las puntuaciones base son Auditoría: 3; Tablero: 5; Derechos de los accionistas: 1; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.